Nobel Prize in Chemistry

Cryo-EM: Visualizing Biomolecules with High-Throughput Single Particle Analysis, Webinar Hosted by Xtalks March 6, 2024

Retrieved on: 
Thursday, February 15, 2024
Protein, Nobel Prize in Chemistry, Data collection, Wild Arms, JEOL, Classification, Cryogenic electron microscopy, Nobel Prize, SPA

TORONTO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- The field of cryogenic electron microscopy (cryo-EM) exploded in popularity during the "resolution revolution" in the 2010s, leading to the 2017 Nobel Prize in Chemistry awarded to Jacques Dubochet, Joachim Frank and Richard Henderson "for developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution." Cryo-EM techniques such as single particle analysis (SPA) now allow structure determination of biomolecules at resolutions previously only reached by X-ray crystallography. Cryo-EM offers many new possibilities as it does not require protein crystallization and allows structural determination of large protein complexes imaged in frozen solution or even in the cellular environment.

Key Points: 
  • The featured speaker will discuss the features of the JEOL CRYO ARM 200kV and 300kV cryo-TEMs.
  • Cryo-EM techniques such as single particle analysis (SPA) now allow structure determination of biomolecules at resolutions previously only reached by X-ray crystallography.
  • Register for this webinar to learn about innovative approaches in cryo-EM, including high-throughput single particle analysis and more.
  • Join Emmanuel Smith, Senior Application Specialist for Cryo-EM, JEOL USA, for the live webinar on Wednesday, March 6, 2024, at 2pm EST (11am PST).

Firefly Bio Debuts With $94 Million Series A Financing

Retrieved on: 
Thursday, February 15, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Therapy, Versant, Merck, MPM, Nobel Prize, Collateral damage, Therapeutic index, Cell, Eli Lilly and Company, ADC, Genentech, Protein, Nobel Prize in Chemistry, Novartis, CSO, Firefly, FireLink, Cancer, Fine chemical

Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.

Key Points: 
  • Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.
  • Firefly has developed a novel platform to treat cancer using degrader antibody conjugates (DACs).
  • Firefly was incubated in close collaboration with scientists at Versant’s Ridgeline Discovery Engine in the Basel Technology Park.
  • “At Firefly, we’ve assembled a unique talent base and platform to significantly advance this promising field,” said Jerel Davis, Ph.D., Managing Director at Versant and a Firefly board member.

Enigma Biomedical - USA Announces Appointment of Hartmuth Kolb, PhD as Chief Scientific Officer

Retrieved on: 
Tuesday, February 13, 2024
Research, General Health, Radiology, Pharmaceutical, Biometrics, Medical Devices, Health Technology, Science, Biotechnology, Neurology, Other Science, Health, Organic chemistry, FNIH, Neuroscience, Doctor of Philosophy, Nobel Prize in Chemistry, NIH, Professor, SVP, Johnson & Johnson, Hartmuth C. Kolb, Neurodegenerative disease, Imperial College London, Biomedicine, Biomarker, Siemens Healthineers, Enigma, EB, Scripps Research, CNS, Associate, Disease, CSO, Diagnosis, PET, Click chemistry, Central nervous system disease, Nobel Prize, Management

Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).

Key Points: 
  • Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).
  • Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.
  • He will join Enigma at the beginning of March, 2024.
  • In his 10 year tenure at Johnson & Johnson Innovative Medicine, he served as the Vice President, Neuroscience Biomarkers and Global Head of Imaging.

Renowned Nobel Laureate Jean-Marie Lehn Appointed Chairman of Syndivia's Scientific Advisory Board

Retrieved on: 
Thursday, November 16, 2023
SAB, Biotechnology, Lehn, Nobel Prize, Spacecraft, Nobel Prize in Chemistry, Drug discovery, Pharmaceutical industry, Management, Chemistry

Professor Lehn, who was awarded the Nobel Prize in Chemistry in 1987 for his groundbreaking work on supramolecular chemistry, brings a wealth of expertise and experience to Syndivia.

Key Points: 
  • Professor Lehn, who was awarded the Nobel Prize in Chemistry in 1987 for his groundbreaking work on supramolecular chemistry, brings a wealth of expertise and experience to Syndivia.
  • His leadership as Chairman of the SAB will play a pivotal role in guiding and advancing Syndivia's cutting-edge research and development initiatives in the field of ADCs.
  • Syndivia's CEO, Sasha Koniev, expressed excitement about the appointment, stating, "We are honored to welcome Professor Jean-Marie Lehn to Syndivia.
  • As Chairman of the SAB, Professor Lehn will work closely with Syndivia's research and development teams, providing strategic insights and fostering collaboration with other scientific leaders.

Quantum Dot Leader Unveils UbiGro® Cover to Enhance Greenhouse Productivity

Retrieved on: 
Wednesday, November 15, 2023
Agriculture, Pressure, Research, Engineering, Food, Traction, Quantum, Nobel Prize, LOS, Nobel Prize in Chemistry, Marketing, Horticulture, Health, Booth, Photosynthesis, ARD International Music Competition, Sunlight, Fluorescence, Chemistry

LOS ALAMOS, N.M., Nov. 15, 2023 /PRNewswire/ -- UbiQD, Inc., the New Mexico-based leader in quantum dot (QD) technology and manufacturing, is today announcing a major step forward for sustainable agriculture. UbiGro Cover is the next evolution in optimizing greenhouse productivity. Expanding on the widely adopted UbiGro Inner—which has revolutionized hundreds of greenhouse spaces worldwide—UbiGro Cover is the latest addition to the greenhouse brand.

Key Points: 
  • UbiGro Cover is the next evolution in optimizing greenhouse productivity.
  • Expanding on the widely adopted UbiGro Inner—which has revolutionized hundreds of greenhouse spaces worldwide—UbiGro Cover is the latest addition to the greenhouse brand.
  • UbiGro Cover integrates fluorescent QD technology into a first-of-its-kind extruded greenhouse cover film, which enables lower prices, wider formats, and higher performance.
  • "Developing a fully extruded yet stable quantum dot greenhouse film was no small feat," said Matt Bergren, UbiQD Chief Product Officer.

Nobel Laureate Hartmut Michel Joins Verseon's Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023
Royal Society, University of Frankfurt Institute for Social Research, Nobel Prize in Chemistry, Max Planck Institute of Biophysics, Foreign, Verseon, Research, German Academy of Sciences at Berlin, German National Academy of Sciences Leopoldina, American Physical Society, Biophysics, Science, University, Max Planck Society, Nobel Prize, Leibniz Prize, Cancer, Tuberculosis, Vaccine, Chemistry

FREMONT, Calif., Nov. 9, 2023 /PRNewswire/ -- Verseon is pleased to announce that Dr. Hartmut Michel, winner of the 1988 Nobel Prize in Chemistry, has joined the company's scientific advisory board. Dr. Michel's work in X-ray crystallography established methodologies for crystallizing cellular membrane proteins and elucidating their structures.

Key Points: 
  • FREMONT, Calif., Nov. 9, 2023 /PRNewswire/ -- Verseon is pleased to announce that Dr. Hartmut Michel, winner of the 1988 Nobel Prize in Chemistry, has joined the company's scientific advisory board.
  • Dr. Michel is a recipient of the Biophysics Prize of the American Physical Society and is one of the original eleven recipients of the Gottfried Wilhelm Leibniz Prize , the highest honor awarded in German scientific research.
  • Verseon's team is excited to have Dr. Michel join the company's scientific advisory board.
  • We are honored to have him on our advisory board."

Nobel Laureate Hartmut Michel Joins Verseon's Scientific Advisory Board

Retrieved on: 
Wednesday, November 8, 2023
Royal Society, University of Frankfurt Institute for Social Research, Nobel Prize in Chemistry, Royal Netherlands Academy of Arts and Sciences, Foreign, Verseon, Research, German Academy of Sciences at Berlin, German National Academy of Sciences Leopoldina, American Physical Society, Biophysics, Science, University, Nobel Prize, Leibniz Prize, Cancer, Tuberculosis, Vaccine, Chemistry

FREMONT, Calif., Nov. 8, 2023 /PRNewswire/ -- Verseon is pleased to announce that Dr. Hartmut Michel, winner of the 1988 Nobel Prize in Chemistry, has joined the company's scientific advisory board. Dr. Michel's work in X-ray crystallography established improved methodologies for crystallizing cellular membrane proteins and elucidating their structures.

Key Points: 
  • FREMONT, Calif., Nov. 8, 2023 /PRNewswire/ -- Verseon is pleased to announce that Dr. Hartmut Michel, winner of the 1988 Nobel Prize in Chemistry, has joined the company's scientific advisory board.
  • Among the many awards and prizes Dr. Michel has received are the Biophysics Prize of the American Physical Society and the Gottfried Wilhelm Leibniz Prize , the highest honor awarded in German scientific research.
  • Verseon's team is excited to have Dr. Michel join the company's scientific advisory board.
  • We are honored to have him on our advisory board."

Foresight Institute Announces 2023 Feynman Prize Winners

Retrieved on: 
Sunday, October 29, 2023
Wyss Institute, Foresight Institute, MacArthur, MIT, Nanotechnology, Collins, Therapy, Life, European Research Council, CRISPR, Broad Institute, Doctor of Philosophy, Research, Internet, Wyss Institute for Biologically Inspired Engineering, Multimedia, Yale University, American Physical Society, Fairy, Feynman Prize in Nanotechnology, University of Luxembourg, Machine learning, Physics, Nanostructure, Teaching, Nobel Prize in Chemistry, University, Nobel Prize, Van der Waals, Synthetic biology, Harvard University, Château, SAN, DNA, Creative industries, Pharmaceutical industry, Auction, Chemistry

SAN FRANCISCO, Oct. 29, 2023 /PRNewswire-PRWeb/ -- Established in 1986, Foresight Institute is a pioneering non-profit organization dedicated to the advancement of molecular manufacturing and transformative technologies. Navigating scientific areas often seen as too ambitious for traditional institutions, Foresight Institute is committed to shaping the long-term future of life through these technologies. Awarded since 1993, Foresight Institute's Feynman Prizes celebrate both established and emerging talents in the field of nanotechnology, embodying their vision of steering transformative technologies to benefit humanity.

Key Points: 
  • SAN FRANCISCO, Oct. 29, 2023 /PRNewswire-PRWeb/ -- Established in 1986, Foresight Institute is a pioneering non-profit organization dedicated to the advancement of molecular manufacturing and transformative technologies.
  • Navigating scientific areas often seen as too ambitious for traditional institutions, Foresight Institute is committed to shaping the long-term future of life through these technologies.
  • Awarded since 1993, Foresight Institute's Feynman Prizes celebrate both established and emerging talents in the field of nanotechnology, embodying their vision of steering transformative technologies to benefit humanity.
  • Foresight Institute also bestows the Distinguished Student Award, spotlighting an upcoming individual for their exceptional work in advancing nanotechnology development and understanding.

ERS Genomics Limited ('ERS') completes licensing agreement with Syngene International

Retrieved on: 
Thursday, October 19, 2023
ERS, Genomics, Nobel Prize in Chemistry, Cas9, Biotechnology, CRISPR, Organization, Research, Development, Drug discovery, Contract research organization, Partnership, Nobel Prize, Biocon, Fine chemical, Pharmaceutical industry, Chemistry

DUBLIN, Oct. 18, 2023 /PRNewswire/ -- ERS Genomics, co-founded by Dr. Emmanuelle Charpentier, a recipient of the 2020 Nobel Prize in Chemistry for her pioneering work on CRISPR/Cas9, provides access to the definitive patent portfolio for this groundbreaking technology.

Key Points: 
  • ERS Genomics Limited ('ERS') completes licensing agreement with Syngene International, India's leading Contract Research, Development and Manufacturing Organization
    Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners.
  • Syngene International Limited, an integrated research, development and manufacturing services company, is poised to leverage the immense potential of CRISPR/Cas9 in various scientific disciplines, including drug discovery, biotechnology, and genomics on behalf of its clients.
  • Mahesh Bhalgat, Chief Operating Officer, Syngene International Limited, said, "Syngene is committed to delivering innovative solutions to our partners worldwide.
  • Our agreement with ERS Genomics underscores this commitment, as we gain access to the most advanced CRISPR/Cas9 technology available.

ERS Genomics Limited ('ERS') completes licensing agreement with Syngene International

Retrieved on: 
Thursday, October 19, 2023
ERS, Genomics, Nobel Prize in Chemistry, Cas9, Biotechnology, CRISPR, Organization, Research, Development, Drug discovery, Contract research organization, Partnership, Nobel Prize, Biocon, Fine chemical, Pharmaceutical industry, Chemistry

DUBLIN, Oct. 18, 2023 /PRNewswire/ -- ERS Genomics, co-founded by Dr. Emmanuelle Charpentier, a recipient of the 2020 Nobel Prize in Chemistry for her pioneering work on CRISPR/Cas9, provides access to the definitive patent portfolio for this groundbreaking technology.

Key Points: 
  • ERS Genomics Limited ('ERS') completes licensing agreement with Syngene International, India's leading Contract Research, Development and Manufacturing Organization
    Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners.
  • Syngene International Limited, an integrated research, development and manufacturing services company, is poised to leverage the immense potential of CRISPR/Cas9 in various scientific disciplines, including drug discovery, biotechnology, and genomics on behalf of its clients.
  • Mahesh Bhalgat, Chief Operating Officer, Syngene International Limited, said, "Syngene is committed to delivering innovative solutions to our partners worldwide.
  • Our agreement with ERS Genomics underscores this commitment, as we gain access to the most advanced CRISPR/Cas9 technology available.